LABD

LABD is entrenched in a pronounced downtrend, with long-term and medium-term bearish structures confirmed by price below all key EMAs and an active Lower Highs & Lower Lows pattern. Short-term rallies into the declining 9/20 EMA zone have been rejected, validating a Sell Now posture on resistance failures at these levels.

• ↑Price up 6.97% to $6.40 on Aug 28, signaling bearish biotech momentum
• ↑Dividend yield of 6.95% provides steady income buffer
• ↓3× inverse leverage risks steep drawdowns on biotech rallies